North American Artificial Intelligence in Diagnostics Market 2020-2026 – ResearchAndMarkets.com
North American Artificial Intelligence in Diagnostics Market 2020-2026 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “North America Artificial Intelligence in Diagnostics Market By Diagnosis Type (Radiology, Oncology, Neurology, Cardiology, Chest & Lungs, Pathology and Other Diagnosis Types), By Component (Services, Software and Hardware), By Country, Industry Analysis and Forecast, 2020-2026” report has been added to ResearchAndMarkets.com’s offering.
The North America Artificial Intelligence in Diagnostics Market is expected to witness market growth of 26.6% CAGR during the forecast period (2020-2026).
AI provides a huge amount of potential for diagnosing neurological conditions. Degenerative neurological disorders such as amyotrophic lateral sclerosis (ALS) can be devastating to the patient. There is currently no treatment for ALS and there are other related medical disorders where correct diagnosis takes time, contributing to higher medical costs. Using the AI tool, ALS and primary lateral sclerosis (PLS) can be easily demarcated and this can help the physician determine the treatment pathway in a much more effective manner. These devices are not currently available.
Machine learning is now used in healthcare to work with vast volumes of data, where the time traditionally expended on porting charts and spreadsheets is now being used to look for clever ways to simplify data processing. It is used to streamline operating practices in hospitals, map and treat infectious disorders, and personalize medical treatments. Machine learning comprises a number of techniques, such as machine learning, supervised learning, unsupervised learning, and advanced learning. Imaging, diagnostics, and product discovery are among the technologies that utilize deep learning.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include General Electric (GE) Co. (GE Healthcare), Siemens AG (Siemens Healthineers), Aidoc Medical Ltd., AliveCor, Inc., Imagen Technologies, Inc., VUNO, Inc., IDx Technologies, Inc., NovaSignal Corporation, Riverain Technologies, LLC, and Zebra Medical Vision Ltd.
Key Topics Covered
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Artificial Intelligence in Diagnostics Market, by Diagnosis Type
1.4.2 North America Artificial Intelligence in Diagnostics Market, by Component
1.4.3 North America Artificial Intelligence in Diagnostics Market, by Country
1.5 Methodology for the Research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis – Global
3.1 Recent Industry Wide Strategic Developments
3.1.1 Partnerships, Collaborations and Agreements
3.1.2 Product Launches and Product Expansions
3.1.3 Approvals
3.2 Top Winning Strategies
3.2.1 Key Leading Strategies: Percentage Distribution (2016-2020)
3.2.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements: 2017, Nov – 2020, Jun) Leading Players
Chapter 4. North America Artificial Intelligence in Diagnostics Market by Diagnosis Type
4.1 North America Radiology Market by Country
4.2 North America Oncology Market by Country
4.3 North America Neurology Market by Country
4.4 North America Cardiology Market by Country
4.5 North America Chest & Lungs Market by Country
4.6 North America Pathology Market by Country
4.7 North America Other Diagnosis Types Market by Country
Chapter 5. North America Artificial Intelligence in Diagnostics Market by Component
5.1 North America Services Market by Country
5.2 North America Software Market by Country
5.3 North America Hardware Market by Country
Chapter 6. North America Artificial Intelligence in Diagnostics Market by Country
6.1 USA Artificial Intelligence in Diagnostics Market
6.2 Canada Artificial Intelligence in Diagnostics Market
6.3 Mexico Artificial Intelligence in Diagnostics Market
6.4 Rest of North America Artificial Intelligence in Diagnostics Market
Chapter 7. Company Profiles
7.1 General Electric (GE) Co. (GE Healthcare)
7.2 Siemens AG (Siemens Healthineers)
7.3 Aidoc Medical Ltd.
7.4 AliveCor, Inc.
7.5 Imagen Technologies, Inc.
7.6 VUNO, Inc.
7.7 IDx Technologies, Inc.
7.8 NovaSignal Corporation
7.9 Riverain Technologies, LLC
7.10 Zebra Medical Vision Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/n0m5r5
Published at Wed, 02 Sep 2020 10:18:45 +0000
Government puts £50m into using AI for disease diagnosis
The government has put £50m into expanding the use of artificial intelligence to diagnose cancer and other diseases.
The funding will be spread across three ‘Centres of Excellence’ in AI imaging and digital pathology that were established in 2018 in Leeds, Coventry, and London. The centres will invest in upgrades to AI and pathology tools that the government claims will benefit up to 26.5 million patients across 38 trusts that will now be given access to the centres’ services.
Increasing the use of technology will allow for quicker and more accurate diagnoses of cancer and other serious diseases, the government indicated. This will help assist its ambition of detecting three in four cases of cancer at an early stage by 2028.
Money provided to the National Pathology Imaging Centre in Leeds will support the facility in “creating a world-leading centre” which will bring together expertise from nine NHS trusts, eight universities, and nine private-sector companies.
Related content
The London Medical Imaging and Artificial Intelligence Centre for Value-Based Healthcare will be given funding to support its use of AI to process medical images and clinical data. The cash boost will enable the centre to “automate expensive and time-consuming manual reporting”.
The use of “NHS pathology data to drive economic growth in health-related AI” will be the focus of the additional money dedicated to Coventry’s Pathology Image Data Lake for Analytics, Knowledge and Education.
The government hopes that the funding will allow the centres to “partner with new and innovative British SMEs”. The improvement to the use of AI also “supports the UK’s long-term response to Covid-19”, it added.
Health and social care secretary Matt Hancock said: “Technology is a force for good in our fight against the deadliest diseases – it can transform and save lives through faster diagnosis, free up clinicians to spend time with their patients and make every pound in the NHS go further. I am determined we do all we can to save lives by spotting cancer sooner. Bringing the benefits of artificial intelligence to the frontline of our health service with this funding is another step in that mission. We can support doctors to improve the care we provide and make Britain a world-leader in this field.
“The NHS is open and I urge anyone who suspects they have symptoms to book an appointment with their GP as soon as possible to benefit from our excellent diagnostics and treatments.”
Professor Reza Razavi, director of the London Medical Imaging and AI Centre for Value-Based Healthcare, added: “Artificial intelligence technology provides significant opportunities to improve diagnostics and therapies as well as reduce administrative costs. With machine learning, we can use existing data to help clinicians better predict when disease will occur, diagnosing and treating it earlier, and personalising treatments, which will be less resource-intensive and provides better health outcomes for our patients.”
Published at Wed, 02 Sep 2020 10:18:45 +0000
